Stock Scorecard
Stock Summary for Genmab (GMAB) - $33.17 as of 10/18/2025 12:31:57 AM EST
Total Score
20 out of 30
Safety Score
68 out of 100
Currently on the following lists
Growth Stock List
Tim's Recommendation
Buy
Growth List Algorithm Criteria for GMAB
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GMAB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GMAB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for GMAB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for GMAB (68 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 9 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 8 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for GMAB
Financial Details for GMAB
Company Overview |
|
|---|---|
| Ticker | GMAB |
| Company Name | Genmab |
| Country | USA |
| Description | Genmab AS is a prominent biotechnology company based in Copenhagen, Denmark, renowned for its innovative development of specialized antibody therapeutics aimed at treating cancer and other critical illnesses. The company boasts a strong pipeline supported by its proprietary technologies and strategic collaborations, driving advancements in next-generation therapies. With a steadfast commitment to improving patient outcomes through targeted immunotherapies, Genmab is well-positioned to capitalize on opportunities within the dynamic oncology sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/6/2025 |
Stock Price History |
|
| Last Day Price | 33.17 |
| Price 4 Years Ago | 39.56 |
| Last Day Price Updated | 10/18/2025 12:31:57 AM EST |
| Last Day Volume | 1,987,313 |
| Average Daily Volume | 2,183,760 |
| 52-Week High | 33.65 |
| 52-Week Low | 17.23 |
| Last Price to 52 Week Low | 92.51% |
Valuation Measures |
|
| Trailing PE | 16.97 |
| Industry PE | 22.69 |
| Sector PE | 40.29 |
| 5-Year Average PE | 34.46 |
| Free Cash Flow Ratio | 2.49 |
| Industry Free Cash Flow Ratio | 14.62 |
| Sector Free Cash Flow Ratio | 29.76 |
| Current Ratio Most Recent Quarter | 6.22 |
| Total Cash Per Share | 13.34 |
| Book Value Per Share Most Recent Quarter | 86.21 |
| Price to Book Ratio | 3.73 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.15 |
| Price to Sales Ratio Twelve Trailing Months | 5.62 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.99 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.11 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 615,546,000 |
| Market Capitalization | 20,417,660,820 |
| Institutional Ownership | 10.44% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 73.20% |
| Annual Earnings Growth | 80.24% |
| Reported EPS 12 Trailing Months | 1.93 |
| Reported EPS Past Year | 0.85 |
| Reported EPS Prior Year | 1.74 |
| Net Income Twelve Trailing Months | 7,435,238,720 |
| Net Income Past Year | 7,844,000,000 |
| Net Income Prior Year | 4,352,000,000 |
| Quarterly Revenue Growth YOY | 18.70% |
| 5-Year Revenue Growth | 32.03% |
| Operating Margin Twelve Trailing Months | 38.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 8,212,777,920 |
| Total Cash Past Year | 9,858,000,000 |
| Total Cash Prior Year | 14,867,000,000 |
| Net Cash Position Most Recent Quarter | 7,275,777,920 |
| Net Cash Position Past Year | 9,858,000,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 937,000,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.97 |
| Total Stockholder Equity Past Year | 36,697,000,000 |
| Total Stockholder Equity Prior Year | 31,610,000,000 |
| Total Stockholder Equity Most Recent Quarter | 33,598,880,040 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 6,678,680,700 |
| Free Cash Flow Per Share Twelve Trailing Months | 10.85 |
| Free Cash Flow Past Year | 7,584,000,000 |
| Free Cash Flow Prior Year | 7,004,000,000 |
Options |
|
| Put/Call Ratio | 0.89 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.48 |
| MACD Signal | 1.56 |
| 20-Day Bollinger Lower Band | 16.69 |
| 20-Day Bollinger Middle Band | 25.05 |
| 20-Day Bollinger Upper Band | 33.40 |
| Beta | 0.82 |
| RSI | 71.69 |
| 50-Day SMA | 29.64 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 30.98 |
System |
|
| Modified | 10/18/2025 12:32:43 AM EST |